StreetInsider.com News Articles

Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Wed, 25 Feb 2026 08:00:00 -0500

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that Artiva management will participate in a fireside chat at the TD Cowen 46^th Annual Health Care Conference on Wednesday, March 4, 2026, at 1:10 p.m. EST, in Boston, MA.

Members of the Artiva management team will also be available to participate in meetings with investors who are registered to attend the conference.

To access the audio webcast

Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

Wed, 25 Feb 2026 08:00:00 -0500

Members of the Artiva management team will also be available to participate in meetings with investors who are registered to attend the conference.

To access the audio webcast

Form 3 Artiva Biotherapeutics, For: Feb 18 Filed by: Huston Thad Allen

Tue, 24 Feb 2026 17:16:00 -0500

si-local-file:///var/storage/secattach/20260224/26053018.html

Form 3 Artiva Biotherapeutics, For: Feb 18 Filed by: Huston Thad Allen

Tue, 24 Feb 2026 17:16:00 -0500

si-local-file:///var/storage/secattach/20260224/26053018.html

Form 8-K Artiva Biotherapeutics, For: Feb 18

Tue, 24 Feb 2026 17:15:00 -0500

si-local-file:///var/storage/secattach/20260224/26052990.html

Form 8-K Artiva Biotherapeutics, For: Feb 18

Tue, 24 Feb 2026 17:15:00 -0500

si-local-file:///var/storage/secattach/20260224/26052990.html

Artiva Biotherapeutics names Thad Huston as chief financial officer

Tue, 24 Feb 2026 08:00:10 -0500

Artiva Biotherapeutics Inc. (NASDAQ: ARTV) appointed Thad Huston as chief financial officer, the clinical-stage biotechnology company announced Monday.

Huston brings more than 30 years of experience in finance, commercial strategy, business development and operations across pharmaceuticals, biotechnology and medical devices. He most recently served as chief financial officer and chief operating officer at Galapagos, where he led finance, commercial operations, quality, IT and business development during the company's transition to an oncology-focused cell therapy organization.

Previously, Huston held finance and IT leadership roles at Kite Pharma, where he supported strategic planning and operational initiatives. He also held senior positions at LivaNova and

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

Tue, 24 Feb 2026 08:00:00 -0500

SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation.

“We are delighted to welcome Thad to Artiva as he brings strong late-stage

Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

Tue, 24 Feb 2026 08:00:00 -0500

“We are delighted to welcome Thad to Artiva as he brings strong late-stage

Form 4 Artiva Biotherapeutics, For: Feb 18 Filed by: Sorg Elaine K.

Thu, 19 Feb 2026 21:50:00 -0500

si-local-file:///var/storage/secattach/20260219/26031948.html

Form 4 Artiva Biotherapeutics, For: Feb 18 Filed by: Sorg Elaine K.

Thu, 19 Feb 2026 21:50:00 -0500

si-local-file:///var/storage/secattach/20260219/26031948.html

Form 3 Artiva Biotherapeutics, For: Feb 18 Filed by: Sorg Elaine K.

Thu, 19 Feb 2026 21:42:00 -0500

si-local-file:///var/storage/secattach/20260219/26031939.html

Form 3 Artiva Biotherapeutics, For: Feb 18 Filed by: Sorg Elaine K.

Thu, 19 Feb 2026 21:42:00 -0500

si-local-file:///var/storage/secattach/20260219/26031939.html

Form 8-K Artiva Biotherapeutics, For: Feb 18

Thu, 19 Feb 2026 17:20:00 -0500

si-local-file:///var/storage/secattach/20260219/26031175.html

Form 8-K Artiva Biotherapeutics, For: Feb 18

Thu, 19 Feb 2026 17:20:00 -0500

si-local-file:///var/storage/secattach/20260219/26031175.html

Artiva Biotherapeutics appoints Elaine Sorg to board of directors

Thu, 19 Feb 2026 08:00:09 -0500

Artiva Biotherapeutics Inc. (NASDAQ: ARTV) announced the appointment of Elaine Sorg to its board of directors. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to the clinical-stage biotechnology company.

Sorg previously led the commercialization of immunology therapies including HUMIRA (adalimumab) and RINVOQ (upadacitinib) for rheumatoid arthritis during her tenure at AbbVie and Eli Lilly. Prior to her retirement in January 2024, she served as senior vice president at AbbVie and president of the company's U.S. commercial operations.

"We are thrilled to welcome Elaine to Artiva's board at such an important time for the company,"

Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

Thu, 19 Feb 2026 08:00:00 -0500

SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA^® (adalimumab) and RINVOQ^® (upadacitinib) for rheumatoid arthritis.

“We are thrilled to welcome Elaine to Artiva’s

Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

Thu, 19 Feb 2026 08:00:00 -0500

“We are thrilled to welcome Elaine to Artiva’s

Form 4 Artiva Biotherapeutics, For: Feb 15 Filed by: Raymon Heather

Wed, 18 Feb 2026 18:51:00 -0500

si-local-file:///var/storage/secattach/20260218/26024209.html

Form 4 Artiva Biotherapeutics, For: Feb 15 Filed by: Raymon Heather

Wed, 18 Feb 2026 18:51:00 -0500

si-local-file:///var/storage/secattach/20260218/26024209.html

Form 4 Artiva Biotherapeutics, For: Feb 15 Filed by: Horan Christopher

Wed, 18 Feb 2026 18:50:00 -0500

si-local-file:///var/storage/secattach/20260218/26024207.html

Form 4 Artiva Biotherapeutics, For: Feb 15 Filed by: Horan Christopher

Wed, 18 Feb 2026 18:50:00 -0500

si-local-file:///var/storage/secattach/20260218/26024207.html

Form 4 Artiva Biotherapeutics, For: Feb 15 Filed by: Banerjee Subhashis

Wed, 18 Feb 2026 18:49:00 -0500

si-local-file:///var/storage/secattach/20260218/26024198.html

Form 4 Artiva Biotherapeutics, For: Feb 15 Filed by: Banerjee Subhashis

Wed, 18 Feb 2026 18:49:00 -0500

si-local-file:///var/storage/secattach/20260218/26024198.html

Form 4 Artiva Biotherapeutics, For: Feb 15 Filed by: Bush Jennifer

Wed, 18 Feb 2026 18:49:00 -0500

si-local-file:///var/storage/secattach/20260218/26024202.html